Paclitaxel-Eluting Stents: Current clinical experience

American Journal of Cardiovascular Drugs

Volumn 4, Issue 6, 2004, Pages 355-360

  Grube, Eberhard ^a   Buellesfeld, Lutz ^a  

^a Heart Center Siegburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; DEXAMETHASONE; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CORONARY STENT; DEVICE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; INTERMETHOD COMPARISON; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; SLOW RELEASE FORMULATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; CORONARY RESTENOSIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PACLITAXEL; POLYMERS; RANDOMIZED CONTROLLED TRIALS; STENTS;

EID: 4444376584     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404060-00003     Document Type: Article

References (20)

1. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45
2. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95 (4): 1869-76
3. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-9
4. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95
5. Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001; 20 (29): 3806-13
6. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36: 2325-32
7. Hong MK, Kornowski R, Bramwell O, et al. Paclitaxel-coated Gianturco-Roubin II stents reduce neointimal hyperplasia in a porcine coronary in-stent model. Coron Artery Dis 2001; 12: 513-5
8. Gershlick A. The ELUTES trial [oral presentation]. 74th Annual Scientific Session of the American Heart Association; 2001 Nov 7-14; Anaheim
9. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107 (4): 517-20
10. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348 (16): 1537-45
11. Mintz GS, Tinana A, Hong MK, et al. Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 108 (11): 1295-8
12. O'Neill WW. The DELIVER trial: a randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. Chicago (IL): American College of Cardiology, 2003
13. Grube E. The DELIVER II study [oral presentation]. 15th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics; 2003 Sep 15-19; Washington, DC
14. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107 (1): 38-42
15. Buellesfeld L, Gerckens U, Muller R, et al. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions: first results of both the clinical and angiographic 18-month follow-up of TAXUS I. Z Kardiol 2003; 92 (10): 825-32
16. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108 (7): 788-94
17. Tanabe K, Serruys PW, Grube E, et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107 (4): 559-64
18. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31
19. Angiotech® Pharmaceuticals, Inc. Angiotech partner announces results from its TAXUS VI drug-eluting stent trial: results support safety and efficacy of moderate-release formulation in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics (media release) [online]. Available from URL: http://www.angiotech.com/?viewpr=482 [Accessed 2004 Oct 18]
20. Boston Scientific Corporation. Boston Scientific announces 30-day safety data from its TAXUS V drug-eluting stent clinical trial (media release) [online]. Available from URL: http://www.bostonscientific.com/common_templates/articleDisplayTemplate. jhtml?task=tskPressRelease.jhtml§ionld=2&relld=24,25& uniqueld= ABPR5435&acceptedWarning=PR [Accessed 2004 Oct 18]